CA-JUNIPER-NETWORKS
23.5.2023 09:01:35 CEST | Business Wire | Press release
Juniper Networks® (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Korian Benelux, part of a major European healthcare and long-term elderly care organization, selected Juniper’s AI-driven enterprise solutions, including wireless and wired access, to optimize network performance and reliability and deliver personalized care for its residents.
More than 11 thousand Korian employees provide care for approximately 15 thousand residents in 173 locations in The Netherlands and Belgium. Korian was drawn to the Mist AI engine with cloud-hosted operations to give its IT team greater insights into user experiences and better troubleshooting for connected medical Wi-Fi devices and phones. The real-time insights, provided by Juniper Mist Wired Assurance, Juniper Mist Wireless Assurance and the Marvis™ Virtual Network Assistant, have simplified troubleshooting at the customer, device and site level for better service quality. By leveraging Mist AI, the Juniper solution delivers customizable service levels and actionable recommendations to proactively fix issues, often before users are impacted. As a result, users experience a more reliable network infrastructure with less downtime, due to the Juniper Mist AI predictive approach. Centralized configuration and zero-touch provisioning simplify onboarding new Juniper access points and switches as facilities are updated. When Korian does a renovation, the network can be installed in one day, compared to two days with their previous wireless solution.
Staying connected to families and friends is important to the well-being of Korian’s residents and short-term recovery patients, whether they like to call, video chat or email. Residents can use tablets in their rooms to watch movies, listen to their favorite music and call the nursing staff if they need help. Voice communications are loud and clear. Families and friends have guest Wi-Fi when they come to visit.
Korian staff have fast, responsive access to their long-term care, clinical and administrative applications, so they can stay productive and focused on patient care. Smart medical devices have the more reliable connectivity necessary for Korian to provide optimal care.
The organization adopted Juniper Wireless Access Points and Wireless Assurance driven by Mist AI to deliver better resident engagement, coupled with industry-leading Wi-Fi that is both more predictable and more reliable. In addition, Juniper Networks EX Series Switches and Juniper Mist Wired Assurance provide high-performance, more secure access to the access points and other wired devices. Juniper was named a Leader in the 2022 Gartner® Magic Quadrant™ for Enterprise Wired and Wireless LAN Infrastructure.
Korian Benelux Group worked with Nomios, a Juniper Elite Plus partner, to create the optimal network architecture, focusing on network design, validation and testing to ensure that the Juniper solutions met strategic and technical goals.
Supporting Quotes:
“With our new network, our nursing staff have resilient access to medical and administrative applications. Computers on wheels and other smart medical equipment are always connected. Residents and their families can now easily connect to the Wi-Fi. IT has clear visibility into service level expectations and what we’re actually delivering. With Juniper Mist, we can see any Wi-Fi problems ourselves immediately, instead of waiting for nursing staff to tell us. Ultimately, we spend less time troubleshooting, and that frees up our time for more strategic priorities.”
- Christoph Van Doren, ICT Director, Korian Benelux
“Healthcare organizations are constantly looking to leverage innovative technology to deliver a high-touch experience for residents, guests and staff. The network plays a vital role at Korian by keeping its technology infrastructure healthy. It allows them to simply scale and support new applications and technologies that can assist in driving better resident outcomes and experiences.”
- Gos Hein van de Wouw, Vice President, Enterprise, EMEA, Juniper Networks
Additional Resources:
- Korian: Success Story
- 2022 Gartner Magic Quadrant for Enterprise Wired and Wireless LAN Infrastructure: View Report
- Blog: When it Comes to Wired & Wireless Access, Juniper Mist is in the Driver’s Seat
- Follow Juniper Networks online: Facebook | Twitter | LinkedIn
- Juniper Blogs and Community: J-Net
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005106/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
